CD11b؉ Gr1 ؉ myeloid-derived suppressor cells (MDSCs), a heterogeneous population of precursor cells, modulate protective immunity against visceral leishmaniasis by suppressing T cell functions. We observed that CD11b ϩ cells have been shown to be essential for the production of early Th1 cytokines in murine draining lymph nodes (14). However, the suppression mechanism of MDSCs includes production of cyclooxygenase-2 (Cox-2) and arginase I and blocking of T cell function by depleting L-arginine (15). Interestingly, pharmacological inhibition of Cox-2 blocked the expression of arginase I in lung carcinoma (16), though it was not clear how suppression of Cox-2 in MDSCs could affect Leishmania infection in a susceptible host.On the other hand, glycyrrhizic acid (GA), a predominant bioactive component of the root of Glycyrrhiza glabra, has been reported to evoke antileishmanial activity through regulation of Cox-2 production (17). MDSCs exert a suppressive function on T cells that is dependent on the production of arginase I (11, 12). We aimed to investigate how MDSCs and their pharmacological manipulation affect the host immune response against L. donovani infection. Here we show that MDSCs from soluble leishmanial antigen (SLA)-immunized BALB/c mice are less immunosuppressive than infection-induced MDSCs and fail to inhibit the induction of Th1 cytokines. Immunization of BALB/c mice with SLA resulted in reduced production of arginase I, Cox-2, inducible nitric oxide synthase (iNOS), and prostaglandin E2 (PGE2) in MDSCs. Moreover, pharmacological inhibition of Cox-2 by GA in BALB/c mice rendered the MDSCs nonsuppressive. In summary, we demonstrated an antileishmanial effect of Cox-2 inhibition by GA in myeloid-derived suppressor cells, a strategy that may be useful for eliminating the suppressive effect of MDSCs in relevant pathological contexts.